Genmab A/ S stock (DK0010272202): Q1 revenue up 25%, pipeline expands to $5B+ potential value

Genmab A/S reported first?quarter 2026 results with 25% revenue growth and an expanding late?stage oncology pipeline valued at over $5 billion, while its U.S.?listed shares traded around $26 after a recent gap?down.

Genmab A/S (NASDAQ: GMAB) reported first?quarter 2026 results on May 7, showing 25% year?on?year revenue growth and an expanding late?stage pipeline with an estimated potential value of more than $5 billion, according to an Investing.com report published on May 8, 2026.Investing.com as of 05/08/2026 The Copenhagen?based biotech emphasized progress across its antibody?based oncology programs, which underpin both current royalty streams and future commercial upside.

On the same day, MarketBeat noted that Genmab shares gapped down before the open on Nasdaq, moving from a prior close of $27.06 to an opening price of $25.56 and trading around $26.03 on volume of about 2.21 million shares.MarketBeat as of 05/08/2026 The stock’s 50?day moving average stood at $27.32 and its 200?day moving average at $29.91, indicating a near?term pullback from longer?term levels.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Genmab A/S
• Sector/industry: Biotechnology / oncology therapeutics
• Headquarters/country: Copenhagen, Denmark
• Core markets: United States, Europe, global oncology markets
• Key revenue drivers: Royalties and milestones from partnered antibody products, late?stage pipeline assets
• Home exchange/listing venue: Nasdaq Copenhagen; also listed on Nasdaq (GMAB)
• Trading currency: USD on Nasdaq; DKK on Nasdaq Copenhagen

Genmab A/S: core business model

Genmab A/S is a Denmark?based biotechnology company focused on the discovery and development of human antibody therapeutics for the treatment of cancer and other serious diseases.justETF as of 05/08/2026 The company’s core business model centers on proprietary antibody platforms such as DuoBody, HexaBody, and T?cell engagers, which it uses to create differentiated molecules that are then advanced either independently or in collaboration with larger pharmaceutical partners.

Through this model, Genmab generates revenue primarily via upfront payments, milestone achievements, and royalties on sales of partnered products, rather than relying on large?scale in?house commercialization.Morningstar as of 05/08/2026 This capital?efficient approach allows the company to maintain a broad pipeline while limiting direct exposure to the high costs of global marketing and distribution.

Main revenue and product drivers for Genmab A/S

Genmab’s main revenue drivers stem from its late?stage oncology assets and established royalty streams on marketed antibody products, including collaborations with major global pharma companies.Investing.com as of 05/08/2026 The reported 25% year?on?year revenue growth in the first quarter of 2026 reflects both higher royalty income and milestone payments tied to clinical and regulatory progress across the portfolio.

The company’s pipeline includes multiple antibody?based candidates in late?stage development, with an estimated potential value exceeding $5 billion, according to the same Investing.com report.Investing.com as of 05/08/2026 These assets span hematologic malignancies and solid tumors, positioning Genmab as a key supplier of next?generation antibody platforms to partners seeking differentiated oncology therapies.

Conclusion

Genmab A/S has delivered 25% year?on?year revenue growth in the first quarter of 2026, supported by an expanding late?stage oncology pipeline with an estimated potential value of more than $5 billion.Investing.com as of 05/08/2026 At the same time, its U.S.?listed shares have recently traded around $26 after a gap?down, reflecting short?term volatility in a biotech name tied to clinical and regulatory catalysts.

For investors, Genmab represents a capital?efficient biotech with a focus on antibody platforms and royalty?based revenue, but its valuation is sensitive to pipeline progress and partner?driven commercial outcomes.Morningstar as of 05/08/2026 The company’s exposure to the U.S. oncology market through Nasdaq listing and major pharma partnerships adds relevance for U.S. retail investors seeking diversified biotech exposure without direct commercial?risk bearing.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.